Search 

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.

We employ over 900 staff and operate from state-of-the-art manufacturing and clinical facilities in the US and UK. Our people make Quotient Sciences a special place to work. We are a dedicated team passionate about innovating and transforming drug development to help our customers develop new medicines for patients in need.

We recruit people that are committed to making a difference, who excel at customer service and are always willing to go the extra mile. Teamwork is integral to our culture and success — helping, supporting and mentoring run through our DNA. Expect to join an empowering and innovative culture, where we encourage continuous improvement and offer opportunities to learn and develop every day.

Albumedix - Dedicated to Better Health

Albumedix is a science-driven, life-science company focused on enabling the creation of advanced therapies and biopharmaceuticals utilizing our high quality recombinant human albumin products and technologies. We believe in empowering excellence to enable advanced therapies and facilitate otherwise unstable drug candidates reach patients worldwide. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical and medical device companies worldwide. Headquartered in Nottingham, England with more than 100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started more than 35 years ago.

Our vision is to empower excellence in how we as a business operate and create products and services of the highest quality; but also to enable our customers and partners to excel in the development of transformative therapies, and thereby support life sciences and patients equally. As an example, we are proud to be working with domestic, national and international life science companies in these challenging times towards the urgent response against covid-19 - be it diagnostically, therapeutically and prophylactically.

Almac Discovery is an innovative biotech company operating within and supported by the Almac Group of companies. It is led by an experienced team (ex Pharma and Biotech), with a track record in delivering successful clinical stage programmes. Almac Discovery utilises its capabilities and expertise to discover and develop novel first-in-class/best-in-class NCEs and Novel Protein Therapeutics through to IND-ready stage, after which it seeks to collaborate with partners to continue into clinical development.

Its core expertise and arising portfolio are focussed on two areas:
a) Targeting the Deubiquitinating enzyme class (DUBs) linked to protein homeostasis and degradation through the application of its proprietary Ubi-Plex technology platform, and,
b) Next Generation Protein:Drug Conjugate (PDC) technology platform utilising minimal antigen-binding domains combined with Almac's novel, proprietary linker and payload technology.   
Drug programmes derived from these platforms are currently being prosecuted both in house and with external collaborators.

Founded in Oxford in 2016, Arctoris is the world’s first fully automated drug discovery platform.

A global team of biotech and pharma veterans and leading engineers developed and operate Ulysses, our proprietary technology platform. Combining robotics, AI and blockchain, Arctoris is the next step in drug discovery evolution.

Arctoris is trusted by biotech and AI-driven drug discovery companies, pharmaceutical corporations and academic centers on three continents to bring new drugs from idea to IND faster.

Aspire Pharma is an innovative, privately owned British pharmaceutical company established in 2009. We develop medicines that make a difference. Our innovative products are difficult to emulate and are the result of teamwork and creative thought.

BioPartner UK is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK life science companies.

BioPartner creates opportunities for international business partnering, operating both independently and in partnership with the UK government to support the UK Life Science sector. We work with a range of clients in the private and public sector to organise partnering events, international projects and missions. BioPartner support extends well beyond single events or missions, providing strategic consultancy, research and reports.

We are accredited by government and operate as a non-profit organisation, but our independence ensures a flexible, rapid response when assisting event managers and providing information about the UK Life Science sector.

bit.bio is an award-winning human synthetic biology enterprise based in Cambridge, UK. bit.bio's mission is to code cells for health. Our breakthrough opti-ox technology platform is capable of producing consistent batches of every human cell. The technology directly reprograms stem cells into other human cell types with consistency at scale.

Having access to human cells has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease and form the basis for a new generation of cell and tissue therapies.

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3(R)) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry.

C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294m.

The Company was founded as a spin-out from the University of Manchester. t has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO.

Crystec Pharma is focused on applying supercritical fluid technology to improve the performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.

Applications of our mSAS® (modified Supercritical Anti-Solvent)  technology include enhancing the dissolution and bioavailability of drugs, optimising release profiles, as well as improving stability and processing characteristics.

Our solutions include the following:

                •    Crystal and particle engineering
                •    Stabilisation of therapeutic agents derived from biotechnology
                •    Polymorph screening
                •    Improved performance of poorly soluble drugs
                •    Improved bioavailabilty of small molecules
                •    Alternative routes of delivery such as inhaled therapy
                •    Taste masking
                •    Crystallisation seeds
                •    Residual solvent elimination